Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca License With Regeneron For VelocImmune Could Spark Industry Trend

This article was originally published in The Pink Sheet Daily

Executive Summary

Regeneron is seeking to sign multiple deals offering access to the next-generation human monoclonal antibody discovery technology, exec tells "The Pink Sheet" DAILY.

You may also be interested in...



Astellas Signs License For Regeneron’s VelocImmune To Bolster Antibody Platform

Deal, valued at potentially $120 million, is Regeneron’s second for the human monoclonal antibody discovery technology.

Astellas Signs License For Regeneron's VelocImmune To Bolster Antibody Platform

Astellas will license Regeneron's human monoclonal antibody discovery technology VelocImmune as part of a strategy to build a new technology platform for the development of antibody drugs, the company said March 30

Astellas Signs License For Regeneron’s VelocImmune To Bolster Antibody Platform

Deal, valued at potentially $120 million, is Regeneron’s second for the human monoclonal antibody discovery technology.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel